P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

• L. H. Sehn,
• K. Hübel,
• S. Luminari,
• A. Salar,
• B. E. Wahlin,
• A. K. Gopal,
• C. Bonnet,
• S. Paneesha,
• M. Trneny,
• H. Mashegu,
• C. Lihou,
• D. Li,
• C. W. Scholz

Affiliations

L. H. Sehn

1 BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, Canada

K. Hübel

2 Department of Internal Medicine I Oncology and Hematology, University Hospital Cologne, Cologne, Germany

S. Luminari

3 Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

A. Salar

4 Department of Haematology, Hospital del Mar-IMIM, Barcelona, Spain

B. E. Wahlin

5 Department of Medicine, Unit of Hematology, Karolinska Institute, Stockholm, Sweden

A. K. Gopal

6 Division of Medical Oncology, University of Washington Medicine, Seattle, United States of America

C. Bonnet

7 Clinical Hematology, Centre Hospitalier Universitaire, University of Liège, Liège, Belgium

S. Paneesha

8 University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

M. Trneny

9 First Department of Medicine, First Faculty of Medicine, Charles University, General Hospital, Prague, Czechia

H. Mashegu

10 Incyte Corporation, Wilmington, United States of America

C. Lihou

10 Incyte Corporation, Wilmington, United States of America

D. Li

10 Incyte Corporation, Wilmington, United States of America

C. W. Scholz

11 Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany